Your session is about to expire
← Back to Search
Dietary Supplement
Can Flaxseed Prevent Broken Hearts in Women With Breast Cancer Study? (CANFLAX Trial)
N/A
Waitlist Available
Led By Davinder S Jassal, MD
Research Sponsored by St. Boniface Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if a drink made from flaxseeds can prevent heart problems in women with early-stage breast cancer who are undergoing specific chemotherapy treatments. The nutrients in flaxseeds may help protect their hearts from damage. Flaxseed has been studied for its potential cardiovascular benefits, including reducing blood pressure, lowering cholesterol levels, and protecting against heart disease.
Eligible Conditions
- Cardiotoxicity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Left ventricular ejection fraction (LVEF) change
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Oat fibre "milk"Experimental Treatment1 Intervention
A total of 30 women will receive the oat fiber "milk" on a daily basis for a total of 4 months. The oat fibre "milk" will be composed of oat fibre, various gums for texture, vanilla flavoring, several minor ingredients, and water.
Group II: Flax "milk"Experimental Treatment1 Intervention
A total of 30 women will receive flax (FLX) "milk" on a daily basis for a total of 4 months. The FLX "milk" will be composed of BevPur (30 mesh FLX), various gums for texture, vanilla flavoring, several minor ingredients, and water. Each serving contains 15 grams of FLX and 3.75 grams of Omega-3.
Find a Location
Who is running the clinical trial?
St. Boniface HospitalLead Sponsor
54 Previous Clinical Trials
14,974 Total Patients Enrolled
2 Trials studying Cardiotoxicity
378 Patients Enrolled for Cardiotoxicity
Davinder S Jassal, MDPrincipal InvestigatorUniversity of Manitoba